Aerie Pharmaceuticals to Participate in Two Investor Conferences in December

IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that company management will participate in the following conferences in December.

• Citi 2016 Global Healthcare Conference
  • Attendee: Richard Rubino, Chief Financial Officer
  • Date: Thursday, December 8, 2016
  • Location: New York, NY
• BMO Capital Markets 2016 Prescription for Success Healthcare Conference
  • Presenter: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer
  • Presentation Date: Wednesday, December 14, 2016
  • Presentation Time: 5:00pm E.T.
  • Location: New York, NY

The BMO Capital Markets 2016 Prescription for Success Healthcare Conference fireside chat discussion will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/. A replay of the webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA filing for Rhopressa™ (netarsudil ophthalmic solution) 0.02% was originally submitted in the third quarter of 2016 and is expected to be resubmitted in January 2017. The second product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa™ and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a Roclatan™ NDA filing is expected to take place near year-end 2017. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161201005128/en/

Aerie Pharmaceuticals
Richard Rubino, 908-947-3540
[email protected]
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Ami Bavishi, 212-213-0006
[email protected]

Source: Aerie Pharmaceuticals, Inc.

You May Also Be Interested In

• Citi reiterates buy rating on Advanced Energy Industries
• GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
• Danny McBride's Don Gato Tequila Teams with Jon Lindsay and Benji Hughes on New Song "Cool Times"